Zheng Haitao

Dr. Zheng Haitao


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2008 in World Journal of Gastroenterology
Verified
Journal Article
Open access
LJLi-Xin Jiang
Li-Xin Jiang
JXJie Xu
Jie Xu
XWXue-Wen Wang
Xue-Wen Wang
FZFu-Run Zhou
Fu-Run Zhou
WGWei Gao
Wei Gao
ZHZheng Haitao
Zheng Haitao
Gastric outlet obstruction caused by heterotopic pancreas: A case report and a quick review

2 March 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
HSHaiqing Sun
Haiqing Sun
XWXiaojie Wang
Xiaojie Wang
GZGuibin Zheng
Guibin Zheng
GWGuochang Wu
Guochang Wu
QZQingdong Zeng
Qingdong Zeng
ZHZheng Haitao
Zheng Haitao
Background: Use of the novel transoral endoscopic thyroidectomy vestibular approach (TOETVA) is increasing worldwide. Although several studies have compared safety and efficacy of TOETVA and other approaches, most focused on comparisons in the context of unilateral thyroidectomy. Therefore, the present study aimed to compare the safety and surgical completeness of TOETVA with conventional open thyroidectomy (COT) in patients with papillary thyroid carcinoma (PTC) undergoing total thyroidectomy and central neck dissection.Methods: The medical records of patients who underwent TOETVA or COT by a single surgeon between June 2017 and October 2021 were retrospectively reviewed. All patients were diagnosed with PTC and underwent total thyroidectomy with central neck dissection. Propensity score-matching (PSM) was used to reduce potential selection bias and to adjust for differences in baseline clinicopathological characteristics.Results: After PSM, 84 (TOETVA: 28; COT: 56) patients remained in the study population. There were no significant differences in sex, mean age, combined thyroiditis, tumor size, capsule invasion, tumor multifocality in the same lobe, or tumor location between the groups. Operative time was longer (190.54 ± 28.26 vs. 123.93 ± 29.78 min, P<0.001), while postoperative drainage volume (161.07 ± 225.30 vs. 71.16 ± 28.56 ml, P=0.045) was greater, in the TOETVA group than in the COT group. The groups exhibited no significant differences in the mean number of central lymph nodes retrieved (9.39 ± 4.01 vs. 10.71 ± 5.17, P=0.202), mean number of metastatic central lymph nodes (1.36 ± 1.93 vs. 1.77 ± 2.31, P=0.421), postoperative mean thyroglobulin levels (0.08 ± 0.24 vs. 0.10 ± 0.27, P=0.686), rate of transient hypoparathyroidism (TOETVA: 67.9% vs. COT: 66.1%, P=0.870), rate of transient vocal cord palsy (TOETVA: 0% vs. COT: 1.8%, P=1.000), or other complications (TOETVA: 3.6% vs. COT: 0%, P=0.333).Conclusions: TOETVA is a safe approach in select patients with PTC and exhibits similar efficacy to COT in terms of surgical completeness.

1 June 2021 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
GZGuibin Zheng
Guibin Zheng
CMChi Ma
Chi Ma
HSHaiqing Sun
Haiqing Sun
GWGuochang Wu
Guochang Wu
YGYawen Guo
Yawen Guo
ZHZheng Haitao
Zheng Haitao

6 July 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
GZGuibin Zheng
Guibin Zheng
HZHua Zhang
Hua Zhang
SHShaolong Hao
Shaolong Hao
CLChengxin Liu
Chengxin Liu
JXJie Xu
Jie Xu
XSXicheng Song
Xicheng Song
Patterns and clinical significance of cervical lymph node metastasis in papillary thyroid cancer patients with Delphian lymph node metastasis Patterns and clinical significance of cervical lymph node metastasis in papillary thyroid cancer patients with Delphian lymph node metastasis

6 May 2011 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
ZHZheng Haitao
Zheng Haitao
YCYu Chen
Yu Chen
SCShaohua Chen
Shaohua Chen
YNYuzhe Niu
Yuzhe Niu
LYLijian Yang
Lijian Yang
YLYangqiu Li
Yangqiu Li
Background: Recently, we clarified at the molecular level novel chromosomal translocation t(14;14)(q11;q32) in a case of Sézary syndrome, which caused a rearrangement from TRAJ7 to the PPP2R5C gene. PPP2R5C is one of the regulatory B subunits of protein phosphatase 2A (PP2A). It plays a crucial role in cell proliferation, differentiation, and transformation. To characterize the expression and distribution of five different transcript variants of the PPP2R5C gene in leukemia, we analyzed the expression level of PPP2R5C in peripheral blood mononuclear cells from 77 patients with de novo leukemia, 26 patients with leukemia in complete remission (CR), and 20 healthy individuals by real-time PCR and identified the different variants of PPP2R5C by RT-PCR. Findings: Significantly higher expression of PPP2R5C was found in AML, CML, T-ALL, and B-CLL groups in comparison with healthy controls. High expression of PPP2R5C was detected in the B-ALL group; however, no significant difference was found compared with the healthy group. The expression level of PPP2R5C in the CML-CR group decreased significantly compared with that in the de novo CML group and was not significantly different from the level in the healthy group. By using different primer pairs that covered different exons, five transcript variants of PPP2R5C could be identified. All variants could be detected in healthy samples as well as in all the leukemia samples, and similar frequencies and distributions of PPP2R5C were indicated. Conclusions: Overexpression of PPP2R5C in T-cell malignancy as well as in myeloid leukemia cells might relate to its proliferation and differentiation. Investigation of the effect of target inhibition of this gene might be beneficial to further characterization of molecular mechanisms and targeted therapy in leukemia.

24 August 2023 in European Radiology
Verified
Journal Article
Closed access
PDF file
TZTianhan Zhou
Tianhan Zhou
LXLei Xu
Lei Xu
JSJingjing Shi
Jingjing Shi
YZYu Zhang
Yu Zhang
XLXiangfeng Lin
Xiangfeng Lin
DLDing-Cun Luo
Ding-Cun Luo